Physician profile
Ann Thrailkill
NPI 1689635963
$4,209.05
in general payments reported to CMS, 2019-2025
24 companies · $1,002 in 2025
The $1,002 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $244 · 2022: $453 · 2023: $991 · 2024: $1,518 · 2025: $1,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,511.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $619.73 | 2023-2025 | Epclusa |
| Abbvie INC. | $452.82 | 2021-2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $358.37 | 2023-2025 | Jynarque |
| Madrigal Pharmaceuticals | $262.37 | 2025 | Rezdiffra |
| Biogen, INC. | $187.57 | 2023-2024 | Spinraza |
| Intercept Pharmaceuticals, INC. | $181.22 | 2023 | Ocaliva |
| Biohaven Pharmaceuticals, INC. | $152.20 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $142.75 | 2024 | Iqirvo |
| Galderma Laboratories, L.P. | $139.54 | 2025 | Nemluvio |
| Edwards Lifesciences Corporation | $136.56 | 2025 | Sapien 3 Ultra Resilia |
| Neurocrine Biosciences, INC. | $135.63 | 2024 | Ingrezza |
| Vertos Medical, INC. | $128.22 | 2022 | |
| Genzyme Corporation | $124.83 | 2024 | |
| Mayne Pharma Commercial LLC | $123.83 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $121.83 | 2024 | Jynarque |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $115.14 | 2025 | Vyvgart |
| Si-Bone, INC. | $112.25 | 2024 | |
| Janssen Pharmaceuticals, INC | $109.29 | 2025 | Spravato |
| Eisai INC. | $108.37 | 2022 | |
| Sage Therapeutics, LLC | $106.67 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.25 | 2023 | Xifaxan |
| Hologic Sales and Service, LLC | $104.91 | 2024 | Aptima |
| Lilly USA, LLC | $91.70 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.00 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Thrailkill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.